Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population

Journal of the American College of Cardiology

Volumn 41, Issue 1, 2003, Pages 113-120

  Nielsen, Olav W ^a,c   McDonagh, Theresa A ^b   Robb, Stephen D ^b   Dargie, Henry J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST;

ADULT; AGED; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION TESTS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037222965     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02625-6     Document Type: Article

References (27)

1. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population-based study. Lancet 2001;358:439-44.
2. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.
3. Nielsen OW, Hilden J, Larsen CT, Hansen JF. Cross-sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 2001;86:172-8.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. Konstam MA, Kronenberg MW, Rousseau MF, et al, the SOLVD (Studies Of Left Ventricular Dysfunction) Investigators. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88 Pt. 1:2277-83.
7. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: Cross-sectional study evaluating a range of diagnostic tests. BMJ 2000;320:220-4.
8. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
9. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Series WHO 1968;56:1-188.
10. Niinuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998;90:89-94.
11. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study. BMJ 2000;320:906-8.
12. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: Cross-sectional study. BMJ 2000;320:985-6.
13. McClure S, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998;317:516-9.
14. Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high-risk population. Eur Heart J 1999;20:1736-44.
15. Yamamoto K, Burnett-JC J, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
16. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
17. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
18. Muders F, Kromer EP, Griese DP, et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997;134:442-9.
19. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
20. Richards AM, Nicholls MG, Yandle TG, et al, the Christchurch Cardioendocrine Research Group. Neuroendocrlne prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999;81:114-20.
21. Hetmanski DJ, Sparrow NJ, Curtis S, Cowley AJ. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart 2000;84:440-1.
22. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21-6.
23. Nielsen OW, Hilden J, Hansen JF. Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice. Heart 2001;86:218-9.
24. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
25. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J 1999;20:447-55.
26. Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC. A rapid-access heart failure clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 2000;2:423-9.
27. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Ouantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.